Phase 4 N=30 An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
HIV-2 Infection
Primary: Death — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
HIV-2 Infection
Primary: Percentage of Participants in Therapeutic Success — 40 percentage of participants
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 2 N=29 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=219 HIV-Tb Confections Among HIV Patients
HIV
Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants
Phase 2 N=581 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
HIV Infections
Primary: Serious Adverse Events — 0; 17; 0; 6 Participants
Phase 2 N=23 Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
HIV Infections
Primary: HIV Viral Load < 400 Copies/ml — 40; 50 percentage of participants
Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Phase 2 N=87 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Smallpox
Primary: Number of Participants With SAEs — 0; 0; 2; 0 Participants
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
Phase 2 N=255 Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
HIV Infections · Hepatitis C · Liver Disease
Primary: Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS) — 0; 0 Metavir units per one year (52 weeks) — p=0.58
Phase 2 N=43 Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
HIV · Human Immunodeficiency Virus
Primary: Time to Virologic Failure After Initiating PRO 140 Monotherapy. — 70.71 days — p=<0.0001
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 3 N=562 Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
HIV
Primary: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure — 0.23; 0.43; 0.45 proportion of…
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Phase 3 N=33 Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
HIV
Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants
Phase 2 N=195 Early ART to Limit Infection and Establishment of Reservoir
HIV-1 Infection
Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48
N/A N=114 Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial
HIV-1
Primary: Number of Participants Reaching Clinical Long Term Component Endpoints — 3; 5; 18; 23 Participants
Phase 3 N=212 HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
Infection, Human Immunodeficiency Virus I · HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks — 81; 82; 19; 18 Percentage of participants
Phase 2 N=148 Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
HIV Infections
Primary: Proportion of Patients Without Failure of Strategy From Week 0 to Week 72 — 73; 55 Pourcentage — p=0.025
Phase 3 N=1,695 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
HIV Infection
Primary: New or Recurrent Disease Progression Events, as Defined, or Death. — 110; 119 Participants — p=0.47
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 2 N=35 Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
Infection, Human Immunodeficiency Virus
Primary: Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — 0.05; -1.51; -2.03; -2.46 Log10 copies/milliliter (log10…
N/A N=774 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
HIV Infections
Primary: Number of Treatment-naïve Participants With Human Immunodeficiency Virus Ribonucleic Acid (HIV-RNA) Levels Less Than (<)50 Copies/Milliliter (c/mL) at 24 Weeks After 2DR…
Phase 3 N=113 Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United…
Phase 2 N=10 Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) — -42095.14; -49065.88; -32947.50; -33149.13 Copies per milliliter